Treatment strategies in myelodysplastic syndromes

被引：10

作者：

Atallah, Ehab ^{[2
]}

Garcia-Manero, Guillermo ^{[1
]}

机构：

[1] Univ Texas Houston, MD Anderson Canc Ctr, DEpt Leukemia, Houston, TX 77030 USA

[2] Med Coll Wisconsin, Dept Neoplast Dis, Milwaukee, WI 53226 USA

来源：

CANCER INVESTIGATION | 2008年 / 26卷 / 02期

关键词：

5-azacytidine; 5-aza-2 '-deoxycytidine; lenalidomide; DNA methylation; myelodysplastic syndromes;

D O I：

10.1080/07357900701788122

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Myelodysplastic syndromes (MDS) are a group of disorders characterized by progressive cytopenias and transformation to acute leukemia. Over the last four years, we have experienced a revolution in the treatment of MDS. Three drugs were approved in the U.S. Two of them, 5-azacitidine and 5-aza-2'-deoxycitidine, induce DNA hypomethylation. The third agent, lenalidomide, is a thalidomide analogue with significant activity in a subset of patients with low-risk MDS, anemia and chromosome 5 alterations. Several other agents are being evaluated in MDS. In this short review, we will summarize our current approach to the therapy of patients with MDS.

引用

页码：208 / 216

页数：9

共 89 条

[1] Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes [J].

Aguayo, A ;

Kantarjian, H ;

Manshouri, T ;

Gidel, C ;

Estey, E ;

Thomas, D ;

Koller, C ;

Estrov, Z ;

O'Brien, S ;

Keating, M ;

Freireich, E ;

Albitar, M .

BLOOD, 2000, 96 (06) :2240-2245

[2] Bone marrow transplantation for myelodysplasia [J].

Anderson, JE .

BLOOD REVIEWS, 2000, 14 (02) :63-77

[3] Allogeneic marrow transplantation for Myelodysplastic syndrome with advanced disease morphology: A phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors [J].

Anderson, JE ;

Appelbaum, FR ;

Schoch, G ;

Gooley, T ;

Anasetti, C ;

Bensinger, WI ;

Bryant, E ;

Buckner, CD ;

Chauncey, T ;

Clift, RA ;

Deeg, HJ ;

Doney, K ;

Flowers, M ;

Hansen, JA ;

Martin, PJ ;

Matthews, DC ;

Nash, RA ;

Sanders, JE ;

Shulman, H ;

Sullivan, KM ;

Witherspoon, RP ;

Storb, R .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) :220-226

[4] Epidemiological features of myelodysplastic syndromes: Results from regional cancer surveys and hospital-based statistics [J].

Aul, C ;

Giagounidis, A ;

Germing, U .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2001, 73 (04) :405-410

[5] PROPOSALS FOR THE CLASSIFICATION OF THE MYELODYSPLASTIC SYNDROMES [J].

BENNETT, JM ;

CATOVSKY, D ;

DANIEL, MT ;

FLANDRIN, G ;

GALTON, DAG ;

GRALNICK, HR ;

SULTAN, C .

BRITISH JOURNAL OF HAEMATOLOGY, 1982, 51 (02) :189-199

[6] Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia [J].

Bibawi, S ;

Abi-Said, D ;

Fayad, L ;

Anderlini, P ;

Ueno, NT ;

Mehra, R ;

Khouri, I ;

Giralt, S ;

Gajewski, J ;

Donato, M ;

Claxton, D ;

Braunschweig, I ;

van Besien, K ;

Andreeff, M ;

Andersson, BS ;

Estey, EH ;

Champlin, R ;

Przepiorka, D .

AMERICAN JOURNAL OF HEMATOLOGY, 2001, 67 (04) :227-233

[7] A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Francais des Myelodysplasies [J].

Bouscary, D ;

Legros, L ;

Tulliez, M ;

Dubois, S ;

Mahe, B ;

Beyne-Rauzy, O ;

Quarre, MC ;

Vassilief, D ;

Varet, B ;

Aouba, A ;

Gardembas, M ;

Giraudier, S ;

Guerci, A ;

Rousselot, P ;

Gaillard, F ;

Moreau, A ;

Rousselet, MC ;

Ifrah, N ;

Fenaux, P ;

Dreyfus, F .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 131 (05) :609-618

[8]

Broliden PA, 2006, HAEMATOLOGICA, V91, P667

[9]

CHOI SH, 2006, ASH ANN M ABSTR, V108, P4303

[10] A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes:: delayed transplantation for low-risk myelodysplasia is associated with improved outcome [J].

Cutler, CS ;

Lee, SJ ;

Greenberg, P ;

Deeg, HJ ;

Pérez, WS ;

Anasetti, C ;

Bolwell, BJ ;

Cairo, MS ;

Gale, RP ;

Klein, JP ;

Lazarus, HM ;

Liesveld, JL ;

McCarthy, PL ;

Milone, GA ;

Rizzo, JD ;

Schultz, KR ;

Trigg, ME ;

Keating, A ;

Weisdorf, DJ ;

Antin, JH ;

Horowitz, MM .

BLOOD, 2004, 104 (02) :579-585

← 1 2 3 4 5 6 7 8 9 →